Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 9484 [2020-03177]
Download as PDF
<![CDATA[
9484
Federal Register / Vol. 85, No. 33 / Wednesday, February 19, 2020 / Notices
on propeller tips, a flotation device if
operated over water, and an ‘‘auto go
home’’ feature in case of loss of control
link or low battery; having an observer
on the lookout for wildlife, people, and
other hazards; and ensuring that the
separation between the operator and
quadcopter does not exceed an
operational range of 500 meters. The
applicant is seeking a Waste Permit to
cover any accidental releases that may
result from operating the RPAS and
ATVs. All waste materials produced
during the marathon activity would be
collected and mitigation measures
would be in place to reduce the
possibility of waste release. The
applicant would provide temporary,
portable toilet facilities to marathon
participants. All human waste generated
would be returned to the ship for
disposal.
Location: King George Island,
Antarctica.
Dates of Permitted Activities: March
23–April 10, 2020.
Erika N. Davis,
Program Specialist, Office of Polar Programs.
[FR Doc. 2020–03165 Filed 2–18–20; 8:45 am]
BILLING CODE 7555–01–P
NUCLEAR REGULATORY
COMMISSION
Advisory Committee on the Medical
Uses of Isotopes: Meeting Notice
U.S. Nuclear Regulatory
Commission.
ACTION: Notice of meeting.
khammond on DSKJM1Z7X2PROD with NOTICES
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) will convene a
meeting of the Advisory Committee on
the Medical Uses of Isotopes (ACMUI)
on March 30–31, 2020. A sample of
agenda items to be discussed during the
public session includes:
(1) A discussion on medical-related
events; (2) a discussion on the ACMUI’s
recommendations regarding the
definition of patient intervention and
other actions exclusive of medical
events; (3) a discussion on the U.S.
Federal Drug Administration’s
regulatory process for drugs and
devices; (4) a discussion on the
overview of the NRC’s Nuclear Material
Events Database; (5) a discussion on the
status of emerging and trending
radiopharmaceuticals; and (6) a
discussion on the ACMUI’s
recommendations on the need for an
interventional radiologist representative
position on the ACMUI.
The agenda is subject to change. The
current agenda and any updates will be
VerDate Sep<11>2014
18:58 Feb 18, 2020
Jkt 250001
available at https://www.nrc.gov/
reading-rm/doc-collections/acmui/
meetings/2020.html or by emailing Ms.
Kellee Jamerson at the contact
information below.
Purpose: Discuss issues related to 10
CFR part 35 Medical Use of Byproduct
Material.
Date and Time: March 30, 2020 from
8:30 a.m. to 2:45 p.m. and March 31,
2020 from 8:30 a.m. to 2:00 p.m. Eastern
Standard Time.
Address for Public Meeting: U.S.
Nuclear Regulatory Commission, Two
White Flint North Building, Room T–
2D30, 11545 Rockville Pike, Rockville,
Maryland 20852.
Public Participation: Any member of
the public who wishes to participate in
the meeting in person or via phone
should contact Ms. Jamerson using the
information below. The meeting will
also be webcast live from the NRC’s
Webcast Portal at https://video.nrc.
gov/. Contact Information: Ms. Kellee
Jamerson, email: Kellee.Jamerson@
nrc.gov, telephone: (301) 415–7408.
Conduct of the Meeting
Darlene F. Metter, M.D. will chair the
meeting. Dr. Metter will conduct the
meeting in a manner that will facilitate
the orderly conduct of business. The
following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a
written statement should submit an
electronic copy to Ms. Jamerson using
the contact information listed above. All
submittals must be received by March
25, 2020, three business days before the
meeting, and must pertain to the topics
on the agenda for the meeting.
2. Questions and comments from
members of the public will be permitted
during the meeting, at the discretion of
the ACMUI Chairman.
3. The draft transcript and meeting
summary will be available on the
ACMUI’s website https://www.nrc.gov/
reading-rm/doc-collections/acmui/
meetings/2020.html on or about May 12,
2020.
4. Persons who require special
services, such as those for the hearing
impaired, should notify Ms. Jamerson of
their planned attendance.
This meeting will be held in
accordance with the Atomic Energy Act
of 1954, as amended (primarily Section
161a); the Federal Advisory Committee
Act (5 U.S.C. App); and the
Commission’s regulations in title 10 of
the Code of Federal Regulations, Part 7.
Dated at Rockville, Maryland this 12th day
of February, 2020.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
For the U.S. Nuclear Regulatory
Commission.
Russell E. Chazell,
Advisory Committee Management Officer.
[FR Doc. 2020–03177 Filed 2–18–20; 8:45 am]
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
[NRC–2012–0110]
An Approach for Plant-Specific, RiskInformed Decisionmaking: Technical
Specifications
Nuclear Regulatory
Commission.
ACTION: Draft regulatory guide; request
for comment.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) is re-issuing for
public comment draft regulatory guide
(DG), DG–1287, ‘‘An Approach for
Plant-Specific, Risk-Informed
Decisionmaking: Technical
Specifications.’’ This proposed Revision
2 of Regulatory Guide (RG) 1.177
includes guidance to develop riskinformed applications for technical
specification (TS) changes that
considers engineering issues and
applies risk insights. This proposed
revision also provides guidance
acceptable to the staff for using risk
information to evaluate changes to
nuclear power plant TS completion
times (CTs) and surveillance frequencies
(SFs) and to assess the impact of such
proposed changes on the risk associated
with plant operation. This DG–1287
supplements the guidance provided in
RG 1.174, ‘‘An Approach for Using
Probabilistic Risk Assessment in RiskInformed Decisions on Plant-Specific
Changes to the Licensing Basis,’’
Revision 3, issued January 2018.
DATES: Submit comments by April 20,
2020. Comments received after this date
will be considered if it is practical to do
so, but the NRC is able to ensure
consideration only for comments
received on or before this date.
Although a time limit is given for
public comment, comments and
suggestions in connection with items for
inclusion in RGs currently being
developed or improvements in all
published RGs are encouraged at any
time.
SUMMARY:
You may submit comments
by any of the following methods:
• Federal Rulemaking Website: Go to
https://www.regulations.gov and search
for Docket ID NRC–2012–0110. Address
questions about NRC docket IDs in
Regulations.gov to Jennifer Borges;
ADDRESSES:
E:\FR\FM\19FEN1.SGM
19FEN1
]]>Agencies
[Federal Register Volume 85, Number 33 (Wednesday, February 19, 2020)]
[Notices]
[Page 9484]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03177]
=======================================================================
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Meeting
Notice
AGENCY: U.S. Nuclear Regulatory Commission.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting
of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on
March 30-31, 2020. A sample of agenda items to be discussed during the
public session includes:
(1) A discussion on medical-related events; (2) a discussion on the
ACMUI's recommendations regarding the definition of patient
intervention and other actions exclusive of medical events; (3) a
discussion on the U.S. Federal Drug Administration's regulatory process
for drugs and devices; (4) a discussion on the overview of the NRC's
Nuclear Material Events Database; (5) a discussion on the status of
emerging and trending radiopharmaceuticals; and (6) a discussion on the
ACMUI's recommendations on the need for an interventional radiologist
representative position on the ACMUI.
The agenda is subject to change. The current agenda and any updates
will be available at https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2020.html or by emailing Ms. Kellee Jamerson at the
contact information below.
Purpose: Discuss issues related to 10 CFR part 35 Medical Use of
Byproduct Material.
Date and Time: March 30, 2020 from 8:30 a.m. to 2:45 p.m. and March
31, 2020 from 8:30 a.m. to 2:00 p.m. Eastern Standard Time.
Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two
White Flint North Building, Room T-2D30, 11545 Rockville Pike,
Rockville, Maryland 20852.
Public Participation: Any member of the public who wishes to
participate in the meeting in person or via phone should contact Ms.
Jamerson using the information below. The meeting will also be webcast
live from the NRC's Webcast Portal at https://video.nrc.gov/ gov/. Contact
Information: Ms. Kellee Jamerson, email: [email protected],
telephone: (301) 415-7408.
Conduct of the Meeting
Darlene F. Metter, M.D. will chair the meeting. Dr. Metter will
conduct the meeting in a manner that will facilitate the orderly
conduct of business. The following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a written statement should submit an
electronic copy to Ms. Jamerson using the contact information listed
above. All submittals must be received by March 25, 2020, three
business days before the meeting, and must pertain to the topics on the
agenda for the meeting.
2. Questions and comments from members of the public will be
permitted during the meeting, at the discretion of the ACMUI Chairman.
3. The draft transcript and meeting summary will be available on
the ACMUI's website https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2020.html on or about May 12, 2020.
4. Persons who require special services, such as those for the
hearing impaired, should notify Ms. Jamerson of their planned
attendance.
This meeting will be held in accordance with the Atomic Energy Act
of 1954, as amended (primarily Section 161a); the Federal Advisory
Committee Act (5 U.S.C. App); and the Commission's regulations in title
10 of the Code of Federal Regulations, Part 7.
Dated at Rockville, Maryland this 12th day of February, 2020.
For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Advisory Committee Management Officer.
[FR Doc. 2020-03177 Filed 2-18-20; 8:45 am]
BILLING CODE 7590-01-P
